- Adjusted EPS was $1.14 for Brown & Brown in 1Q, which was an improvement from 84c y/y, and beat the estimated $1.04.
- Organic revenue was shown to have grown by +8.6%, over the estimated +6.55%.
- The revenue for the first quarter was $1.26 billion, a growth of +13% y/y, over the estimated $1.22 billion.
- EBITDAC margin was at 36.9%, an improvement from 34.9% y/y.
- Compensation expenses were at $631 million, a climb of +10% y/y, which was more than the estimated $607.3 million.
- Analyst consensus consisted of 6 buys, 5 holds and 2 sells.
A look at Brown & Brown Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Brown & Brown shows a promising long-term outlook. With a solid Growth score of 4 and a top-notch Momentum score of 5, the company appears to be positioned well for expansion and market performance. Moreover, its Resilience score of 3 signifies a moderate ability to weather economic uncertainties, enhancing its stability. Although the Value and Dividend scores are on the lower side at 2 each, the company’s focus on growth and market momentum bodes well for its future prospects.
Brown & Brown, Inc., known for offering insurance and reinsurance products along with risk management and healthcare services, is strategically positioned to capitalize on growth opportunities. With a nationwide presence in the United States through its various offices, the company is poised to leverage its strong Growth and Momentum scores to drive its business forward in the long term, supported by its moderate Resilience score. While there is room for improvement in Value and Dividend scores, the overall outlook for Brown & Brown seems optimistic based on its Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
